Benny Landa feels confused. The successful entrepreneur, one of the fathers of Israel’s digital printing equipment industry, does not quite understand why Israel’s Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) insists on acquiring US rival Mylan (MYL).
READ MORE:
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
In late 2013, Landa became an activist investor in Teva because of his dissatisfaction with the performance of its board of directors, chiefly over the ouster of Jeremy Levin as CEO.
Since then, Phillip Frost has been replaced as chairman of Teva by former Cellcom Israel Ltd. (NYSE:CEL; TASE:CEL) CEO Yitzhak Peterburg, and Erez Vigodman, who formerly headed Makhteshim-Agan, took over as CEO fifteen months ago….
Published by Globes [online], Israel business news – www.globes-online.com
